As of 2026-11-15, the Relative Valuation of Kinnate Biopharma Inc (KNTE) is (66.51) USD. This relative valuation is based on P/E multiples. With the latest stock price at 2.65 USD, the upside of Kinnate Biopharma Inc based on Relative Valuation is -2609.8%.
The range of the Relative Valuation is (62.57) - (72.74) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 25.4x - 31.3x | 26.8x |
| Forward P/E multiples | 26.2x - 30.5x | 28.9x |
| Fair Price | (62.57) - (72.74) | (66.51) |
| Upside | -2461.1% - -2845.0% | -2609.8% |
| Date | P/E |